Brainstorm Cell Therapeutics (NASDAQ:BCLI) issued its earnings results on Tuesday. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.12), Bloomberg Earnings reports.
NASDAQ:BCLI traded down $0.07 during trading hours on Wednesday, hitting $3.70. 234 shares of the company were exchanged, compared to its average volume of 91,868. The company has a quick ratio of 0.97, a current ratio of 0.97 and a debt-to-equity ratio of 9.34. Brainstorm Cell Therapeutics has a one year low of $2.92 and a one year high of $4.50. The business’s fifty day moving average is $3.99.
Several equities research analysts recently weighed in on the company. Maxim Group reissued a “buy” rating and set a $9.00 price objective on shares of Brainstorm Cell Therapeutics in a report on Tuesday, May 14th. ValuEngine downgraded Brainstorm Cell Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 3rd.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.
Featured Story: Producer Price Index (PPI)
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.